Last reviewed · How we verify
beclomethasone/salbutamol combination
Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle.
Beclomethasone is a corticosteroid that reduces inflammation, while salbutamol is a beta-2 adrenergic receptor agonist that relaxes airway smooth muscle. Used for Maintenance and relief of asthma symptoms, Maintenance and relief of chronic obstructive pulmonary disease (COPD) symptoms.
At a glance
| Generic name | beclomethasone/salbutamol combination |
|---|---|
| Sponsor | Chiesi Farmaceutici S.p.A. |
| Drug class | Corticosteroid/beta-2 adrenergic receptor agonist combination |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
Beclomethasone works by inhibiting the release of pro-inflammatory cytokines, thereby reducing inflammation in the airways. Salbutamol, on the other hand, stimulates the beta-2 adrenergic receptors, leading to relaxation of airway smooth muscle and bronchodilation.
Approved indications
- Maintenance and relief of asthma symptoms
- Maintenance and relief of chronic obstructive pulmonary disease (COPD) symptoms
Common side effects
- Oral candidiasis
- Headache
- Cough
- Throat irritation
- Dysphonia
Key clinical trials
- Anti-Inflammatory Reliever South Africa (PHASE3)
- Individualizing Treatment for Asthma in Primary Care (Full Study) (PHASE4)
- Individualizing Treatment for Asthma in Primary Care (PHASE4)
- CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma (PHASE2)
- Inhaled Long-acting Bronchodilators With or Without Inhaled Glucocorticosteroids for Preventing Hospitalizations and Death in Elderly Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
- Study of the Effect of Mometasone Furoate/Formoterol (MF/F), Montelukast and Beclomethasone Dipropionate (BDP) on Plasma Cortisol Levels of Children 5-11 Years Old With Persistent Asthma (P05574) (PHASE2)
- Non-invasive Measures of Distal Lung Disease in Asthmatics (PHASE4)
- Personalized Treatment Algorithms for Difficult-to-treat Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: